{"id":25235,"date":"2024-04-03T14:59:40","date_gmt":"2024-04-03T14:59:40","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=25235"},"modified":"2025-07-23T10:39:41","modified_gmt":"2025-07-23T08:39:41","slug":"ensayos-clinicos-huidagene","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/es\/ensayos-clinicos-huidagene\/","title":{"rendered":"HuidaGene: hacia los ensayos cl\u00ednicos"},"content":{"rendered":"

En febrero de 2024, David Covini, Presidente de DupMECP2, visit\u00f3 la empresa biotecnol\u00f3gica HuidaGene Therapeutics en Shangh\u00e1i. La visita fue una oportunidad \u00fanica para conocer a un equipo din\u00e1mico cuyo candidato cl\u00ednico puede revolucionar el futuro del tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2 (SMD). <\/p>\n\n\n\n

Dirigida por el Dr. Alvin Luk, Consejero Delegado de HuidagGene, la empresa est\u00e1 a la vanguardia del desarrollo de una tecnolog\u00eda revolucionaria que podr\u00eda cambiar la vida de los ni\u00f1os afectados por SMD. La visita fue una oportunidad incre\u00edble para descubrir las instalaciones de vanguardia y el entorno creativo que respalda este tipo de investigaci\u00f3n. En particular, las oficinas cuentan incluso con un roc\u00f3dromo que fomenta un ambiente de trabajo creativo. <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Alvin y su Directora M\u00e9dica de SMD, la Dra. Gloria Tang, presentaron los detalles de la tecnolog\u00eda de edici\u00f3n de ARN CRISPR CAS13 para el s\u00edndrome de duplicaci\u00f3n de genes. MECP2<\/em>denominado HG204. La prometedora calidad de los datos y los resultados preliminares de los estudios de toxicidad en primates no humanos han llevado a HuidaGene a un desarrollo apasionante. El ensayo cl\u00ednico de la empresa, cuyo inicio est\u00e1 previsto inicialmente para el segundo semestre de 2024, ya ha recibido la aprobaci\u00f3n del comit\u00e9 \u00e9tico de dos hospitales, con el objetivo de incluir a pacientes con SMD antes de finales de a\u00f1o.<\/p>\n\n\n\n

Se trata de una excelente noticia para la comunidad de los SMD. El pr\u00f3ximo ensayo cl\u00ednico del HG204 para los SMD, denominado \"HERO\", tratar\u00e1 inicialmente al menos a 4 pacientes que ser\u00e1n objeto de un estrecho seguimiento durante un a\u00f1o. La primera fase de este ensayo innovador se llevar\u00e1 a cabo en China. La inclusi\u00f3n de m\u00e1s pacientes en China depender\u00e1 de los primeros resultados preliminares del estudio de intervenci\u00f3n.<\/p>\n\n\n\n

HuidaGene ya ha hecho progresos significativos hacia la aprobaci\u00f3n reglamentaria, obteniendo dos designaciones de la FDA (Designaci\u00f3n de Enfermedad Pedi\u00e1trica Rara (RPDD) y Designaci\u00f3n de Medicamento Hu\u00e9rfano (ODD)) para el HG204. Tambi\u00e9n han iniciado contactos con la FDA y la EMA para realizar estudios adicionales en EE.UU. y Europa. <\/p>\n\n\n\n

Es un privilegio haber tenido la oportunidad de conocer a Alvin y Gloria en persona. Estamos encantados de formar parte de esta aventura y esperamos mantener informada a nuestra comunidad sobre los avances de esta tecnolog\u00eda que puede cambiar vidas\".<\/p>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l’entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont […]<\/p>","protected":false},"author":1,"featured_media":25367,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-25235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"\nHuidaGene: vers les essais cliniques - DupMECP2<\/title>\n<meta name=\"description\" content=\"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/es\/ensayos-clinicos-huidagene\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HuidaGene: vers les essais cliniques - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/es\/ensayos-clinicos-huidagene\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T14:59:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T08:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"HuidaGene: vers les essais cliniques\",\"datePublished\":\"2024-04-03T14:59:40+00:00\",\"dateModified\":\"2025-07-23T08:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\",\"url\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\",\"name\":\"HuidaGene: vers les essais cliniques - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"datePublished\":\"2024-04-03T14:59:40+00:00\",\"dateModified\":\"2025-07-23T08:39:41+00:00\",\"description\":\"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"HuidaGene: vers les essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/es\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HuidaGene: hacia los ensayos cl\u00ednicos - DupMECP2","description":"En febrero de 2024, David Covini, Presidente de DupMECP2, visit\u00f3 la empresa biotecnol\u00f3gica HuidaGene Therapeutics en Shangh\u00e1i. La visita fue una oportunidad \u00fanica para conocer a un equipo din\u00e1mico cuyo candidato cl\u00ednico puede revolucionar el futuro del tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2 (SMD).\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/es\/ensayos-clinicos-huidagene\/","og_locale":"es_ES","og_type":"article","og_title":"HuidaGene: vers les essais cliniques - DupMECP2","og_description":"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0","og_url":"https:\/\/dupmecp2.eu\/es\/ensayos-clinicos-huidagene\/","og_site_name":"DupMECP2","article_published_time":"2024-04-03T14:59:40+00:00","article_modified_time":"2025-07-23T08:39:41+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Caroline","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"HuidaGene: vers les essais cliniques","datePublished":"2024-04-03T14:59:40+00:00","dateModified":"2025-07-23T08:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/","url":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/","name":"HuidaGene: hacia los ensayos cl\u00ednicos - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","datePublished":"2024-04-03T14:59:40+00:00","dateModified":"2025-07-23T08:39:41+00:00","description":"En febrero de 2024, David Covini, Presidente de DupMECP2, visit\u00f3 la empresa biotecnol\u00f3gica HuidaGene Therapeutics en Shangh\u00e1i. La visita fue una oportunidad \u00fanica para conocer a un equipo din\u00e1mico cuyo candidato cl\u00ednico puede revolucionar el futuro del tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2 (SMD).\u00a0","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"HuidaGene: vers les essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/es\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/25235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/comments?post=25235"}],"version-history":[{"count":1,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/25235\/revisions"}],"predecessor-version":[{"id":33411,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/25235\/revisions\/33411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/media\/25367"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/media?parent=25235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/categories?post=25235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/tags?post=25235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}